U.S. Banks Stock News

Abbott Laboratories (NYSE:ABT) received FDA authorization for its Libre Duo 10 Day system, described as the world's first dual glucose ketone sensing biowearable for diabetes management. The Libre Duo 10 Day device is designed to continuously track both glucose and ketone levels to help address risks linked to diabetic ketoacidosis. Abbott plans a U.S. launch of Libre Duo 10 Day following the FDA authorization, adding a new offering to its digital health and diagnostics portfolio. Investors...

Bronstein, Gewirtz & Grossman, LLC has filed a past class action lawsuit against Pentwater Capital Management LP and CEO Matthew Halbower, alleging deceptive trading practices that artificially inflated Avis Budget Group’s share price via aggressive purchases and a short squeeze, affecting investors between February 20, 2025 and April 21, 2026. This case focuses attention on how trading behavior by a major shareholder, rather than Avis’s operations, may have influenced investor outcomes...

CRISPR Therapeutics previously secured expanded FDA approval for its ex vivo gene-editing therapy Casgevy, extending use to younger sickle cell disease and beta thalassemia patients. This broader label meaningfully enlarges the addressable treatment pool and further validates CRISPR-based therapies in areas with high unmet medical need. We’ll now examine how this expanded FDA approval for Casgevy could reshape CRISPR Therapeutics’ investment narrative and long-term commercial positioning...

Steel Dynamics (STLD) stock is moving after President Donald Trump proposed 50% tariffs on Canadian steel and vehicles starting in 2027. This policy change could reshape competitive pressure for this major US steel producer. At a share price of $231.08, Steel Dynamics has seen short term share price pressure, with the 7 day and 90 day share price returns down 7.5% and 10.5% respectively. However, the year to date share price return of 31.3% and 1 year total shareholder return of 77.5%...

McKesson (NYSE:MCK) announced a deal to acquire Precision Medicine Group to expand its oncology and clinical research services. The transaction is expected to broaden McKesson's role in personalized medicine, clinical trial support, and biopharma commercialization. The acquisition aligns with McKesson's focus on specialty care and could reshape its position across oncology and research services. McKesson is only one example of how large healthcare players are leaning into data driven...

Indivior Pharmaceuticals has delivered a strong 172.0% total return over the past 5 years, yet the stock now screens as undervalued on broader checks after a recent pullback. With a value score in the high range and the share price giving back some ground in recent weeks, investors are weighing whether the market is still underpricing the business. Indivior Pharmaceuticals is up 172.0% over 5 years, which signals that long term holders have already seen substantial gains even before...

Coinbase Global has delivered a very strong 3 year share price gain while the valuation checks lean expensive and recent shorter term returns have been weaker. For investors looking at Coinbase stock today, the key issue is whether that past strength already prices in a lot of optimism. Coinbase Global is up about 121% over the past 3 years, which puts a spotlight on whether the current valuation leaves much room for error. Progress on crypto regulation, such as the proposed CLARITY Act, and...

SentinelOne earnings event puts AI security growth and profitability in focus SentinelOne (S) is approaching its Q2 fiscal 2027 earnings release, with management indicating expected revenue of US$289 million to US$291 million and adjusted earnings of US$0.06 to US$0.08 per share. This update centers on how that upcoming report may reflect momentum in SentinelOne's AI, data, and cloud security offerings, along with the impact of ongoing cost and productivity initiatives on the company’s...

We wouldn't blame Viavi Solutions Inc. ( NASDAQ:VIAV ) shareholders if they were a little worried about the fact that...

ABM Industries stock has delivered a 9.2% total return over the past 3 years, yet recent short term softness and a high value score suggest the shares may lean cheap rather than stretched at around US$46.59. The 9.2% return over 3 years points to steady but unspectacular shareholder gains that do not obviously signal a euphoric pricing of ABM Industries. Expectations for dependable facility services demand can support earnings resilience. At the same time, any sustained pressure on labor...

Amazon.com (NasdaqGS:AMZN) CEO has highlighted the company’s in-house data center chip business as a rapidly growing, standalone-caliber operation. The move positions Amazon as a competitive force against Nvidia in the AI chip market. The internal chip effort is closely tied to Amazon Web Services and its AI infrastructure offerings. For a fuller view of how this AI hardware push connects with other companies building the compute backbone for machine learning, you can compare a wider group...

Aflac (AFL) has drawn fresh investor attention after recent trading left the stock about 7.5% lower over the past month, even as its past 3 months and 1 year total returns remain positive. At the current share price of $116.18, Aflac’s recent 7 day and 1 month share price returns, both in decline, mark a pullback against a still positive year to date share price return and a multiyear total shareholder return that has remained strongly positive. Look beyond Aflac’s pullback and compare this...

In August 2026, Progress Software released a major update to its Telerik and Kendo UI product lines, embedding context-aware AI into UI generation, debugging, accessibility, legacy app modernization and RAG-powered data interaction for .NET developers. The same week, the company appointed veteran technology leader Bridget Collins as CIO to drive internal AI adoption and cybersecurity, aligning Progress Software’s own operations with the AI-first development capabilities it now offers...

Cheniere Energy has delivered a very strong 5 year share price run, yet current valuation checks flag the stock as leaning expensive even though its earnings multiples still screen as modestly undervalued. For investors, that mix of past returns and mixed valuation signals makes it important to separate durable cash flow expectations from shorter term sentiment around liquefied natural gas trading and derivatives. Cheniere Energy has returned 235.1% over the past 5 years, which puts recent...

Brinker International’s August 2026 results showed fourth-quarter revenue rising to US$1,535.8 million and net income to US$131.1 million, with full-year revenue at US$5.81 billion and net income at US$487.0 million despite higher impairment charges. Alongside these results, the company issued fiscal 2027 revenue guidance of US$6.15 billion to US$6.27 billion, signaling management’s confidence in sustaining recent operating momentum. We’ll now examine how Brinker's stronger earnings and new...

Space Exploration Technologies stock has rebounded over the past month, yet the valuation checks lean expensive and raise questions about how much optimism is already reflected in the price. The share price is up 19.9% over the past month, which puts recent momentum firmly on the side of Space Exploration Technologies after a weaker start to the year. Big capital plans for projects such as the proposed Starbase Louisiana spaceport and expansion in AI and orbital compute can support long run...

COMPASS Pathways (NasdaqGS:CMPS) is back in focus as investors watch the final stages of its planned FDA application for COMP360, a synthetic psilocybin treatment for people with treatment-resistant depression. Over the past year, COMPASS Pathways has seen strong momentum, with a year to date share price return of 127.18% and a 1 year total shareholder return of 212.61%. The recent 32.15% 30 day share price return suggests that enthusiasm around the FDA submission is building further. Scan...

Patterson-UTI Energy (PTEN) is back in focus after strong quarterly results helped trigger a 41.1% share price gain over six months, despite ongoing concerns around profitability quality and free cash flow generation. Zooming out, Patterson-UTI Energy’s recent 12.94% 1 month share price return and 78.05% year to date share price return contrast with a weaker 3 year total shareholder return. This signals strong recent momentum as investors reassess growth prospects and risks around cash...

Western Digital stock has posted extremely strong multi year gains. However, recent pullbacks and a high value score now leave investors asking whether the current price still reflects an attractive entry point or a period of consolidation after a very sharp run. Western Digital has returned about 13x over the past three years, which puts recent short term weakness in the context of a very strong multi year rerating. Growing focus on AI data infrastructure and partnerships such as the new AI...

Fresh attention on Globe Life (GL) comes as its health insurance segment shows strong momentum, with higher health premium revenues, firm Medicare Supplement demand, and broader distribution helping offset pressure from medical inflation. Globe Life's recent share price has eased, with a 7 day share price return of down 3.28% and a 1 day move of down 0.51%. However, the 90 day share price return of 11.56% and year to date share price return of 24.43% point to momentum that aligns with a 1...

Sharplink stock has posted a sharp recovery in recent weeks, yet its long term record and current valuation checks suggest the shares still screen as expensive rather than a clear bargain. For investors looking at Sharplink today, the key issue is how to balance a recent rebound against years of very weak returns. Over the past 5 years, Sharplink has fallen about 98.8%, which points to very heavy value erosion for long term holders. The recent decision to expand its Ethereum treasury and...

Klarna Group (KLAR) is drawing fresh attention after a sharp swing in its story. The company reported a return to profitability and an earnings beat, then cut full year guidance and outlined upcoming CFO and CMO transitions. The mixed signals are clearly showing up in Klarna Group’s share price. Despite the Q2 earnings beat, return to profitability and new membership tiers, the stock’s 30 day share price return is down 17.8%, and the year to date share price return has fallen 50.1%. This...

In the last week, the United States market has stayed flat, yet it is up 18% over the past year with earnings expected to grow by 17% annually in the coming years. In this context of steady growth and potential future gains, identifying small-cap stocks with notable insider activity can provide investors with opportunities to explore potentially undervalued assets.

The United States market remained flat over the last week but has risen by 18% over the past year, with earnings forecasted to grow by 17% annually. In this environment, identifying stocks that are potentially priced below their estimated value can be an effective strategy for investors looking to capitalize on future growth opportunities.